網頁2024年2月11日 · "In our phase-one trial of the Steripath Gen2, our phlebotomy team was able to reduce the blood culture contamination rate to zero when the Steripath device was used in 4,462 blood cultures." 網頁2024年1月19日 · Kurin Inc. announced published results showing that its blood culture collection innovation drastically reduced contamination rates. Contacts Matt Heindel Kurin, Inc. 858-752-9514 mattheindel ...
Magnolia Medical Expands Steripath® Micro Initial Specimen Diversion Device…
網頁2024年8月3日 · A patent that Magnolia Medical Technologies holds for its Steripath blood specimen diversion device for blood tests is valid, and competitor Kurin owes the company $2.1 million in royalties, according to a federal court verdict. Upgrade to Device Daily Bulletin Premium to get all the articles in the free publication PLUS more in-depth stories on … 網頁compromise the sensitivity of blood culture tests 29 and had the potential to be cost-saving due to the small device cost ... costs from $4,500 -13,000 per contaminant. 2, 4 , 6,7 … chargertv
Magnolia Medical Launches New Steripath Micro Initial Specimen Diversion Device …
網頁2024年3月28日 · Steripath Gen2 is the simple, all-in-one solution clinically proven to reduce false-positive blood culture results. Actively diverts and sequesters the initial 1.5-2.0mL of blood, the volume known to contain contaminants.³ Blood cultures are then collected through a second flow path, creating a closed vein-to-bottle collection system. 網頁2024年8月30日 · SEATTLE, Aug. 30, 2024 /PRNewswire/ -- Magnolia Medical Technologies today announced the successful national launch and adoption of Steripath® Gen2. The next generation Initial Specimen Diversion ... 網頁2024年4月6日 · Novel Study Demonstrates the Hospital-Wide Impact of the Steripath® Initial Specimen Diversion Device® on Blood ... United Hospital Center estimated a mean … harrison ford marvel ross